Description
The authors performed a retrospective analysis of the reproducibility of programmed stimulation for the first induction of ventricular tachycardia in those with and without intervening voltage mapping. This was study was not randomized. All subjects had 2 rounds of programmed stimulation separated in time. One group underwent intracardiac echocardiographic mapping in between attempts while the other underwent substrate mapping. The authors found a change in the results of programed stimulation (to either a different VT, or to non-inducibility) more frequently after substrate mapping.
Learning Objectives
- Recognize the mechanical effects of substrate mapping on inducibility of ventricular tachycardia.
Article Authors and Podcast Contributors
Article Authors
Asad A. Aboud, MD, Giovanni Davogustto, MD, Oluwaseun Adeola, MD, Travis D. Richardson, MD, Kenichi Tokutake, MD, Gregory F. Michaud, MD, William G. Stevenson, MD, Arvindh Kanagasundram, MD
Podcast Contributors
Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College
David S. Frankel, MD, FHRS, of the Hospital of the University of Pennsylvania
Usha B. Tedrow, MD, MS, FHRS, of Brigham and Women's Hospital
Disclosure Policy
ACE Disclosure Policy
The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.
Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.
ACCME Definition:
*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Examples of such organizations include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
All relevant financial relationships have been mitigated.Host Disclosure(s):
J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Aboot, Phillips; Stocks (Privately Held): Atlas 5D
Contributor Disclosure(s):
D. Frankel: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Medtronic, Abbott Medical, Stryker, Boston Scientific
U. Tedrow: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., St. Jude Medical, Thermedical, Medtronic, Boston Scientific, Baylis Medical Company
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.